drugset / Trial / NCT02689219
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
Timeline
- Start
- 2016-03-09
- Primary completion
- 2018-11-13
- Completion
- 2019-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |